Senior U.S. trade and health officials are expected to meet with the German government in mid-November for talks on its drug pricing policies, a German government spokesperson confirmed to POLITICO. The talks come as Germany races to avoid U.S. tariffs if it does not reach an agreement with Washington — after the Trump administration launched a trade investigation into Berlin’s pricing policies in June. The Trump administration alleges Germany underpays for new drugs, leaving the U.S. to shoulder a disproportionate share of the global cost of developing innovative medicines. As part of consultations required under Section 301 probes, a meeting between U.S.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.